Methods and compositions for the prevention and treatment of sepsis

• US 8,329,169 B2
• Filed: 05/14/2004
• Issued: 12/11/2012
• Est. Priority Date: 05/15/2003
• Status: Expired due to Fees

• Current Assignee: Genentech, Inc. (Roche Holding AG)
• Original Assignee: Genentech, Inc. (Roche Holding AG)
• Inventors: Fung, Sek Chung, Mollnes, Tom Eirik
• Primary Examiner(s): OGUNBIYI, OLUWATOSIN A
• Application Number:
  US10/556,998
• Publication Number:
  US 20070274989A1
• Time in Patent Office: 3,133 Days
• Field of Search: None
• US Class Current: 424/130.1
• CPC Class Codes: A61P 31/00 Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: A61P 37/04 Immunostimulants
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 7/00 Drugs for disorders of the blood or the extracellular fluid
• CPC Class Codes: C07K 16/18 against material from animals or humans
• CPC Class Codes: C07K 16/2896 against molecules with a "CD"-designation, not provided for elsewhere

Abstract

The present invention includes compositions comprising one or more complement inhibitors and one or more CD14 pathway inhibitors for the prevention or treatment of sepsis. The complement inhibitors may be antibodies that bind to and inhibit complement proteins such as C5a and the CD14 pathway inhibitors may be antibodies that bind to and inhibit CD14 pathway components, such as CD14 and LPS. The invention also relates to methods of treating subjects suffering from sepsis comprising administering these compositions, as well as kits for supplying the compositions for treatment.

Claims

1. A composition for administration to a patient in need thereof for the prevention or treatment of sepsis comprising a complement inhibitor, and a CD14 pathway inhibitor,

wherein the complement inhibitor is an anti-C5a antibody or a binding fragment thereof,

wherein the CD14 pathway inhibitor is an anti-CD14 antibody or a binding fragment thereof,

wherein the sepsis is induced by gram negative bacteria, and

wherein the composition can be administered by oral, rectal, nasal, topical, intradermal, subcutaneous, intravenous, intramuscular, intratracheal, or intraperitoneal means.

2. The composition of claim 1, wherein said anti-CD14 antibody has altered effector functions of the Fc region.

4. The composition of claim 1 or 3, further comprising one or more pharmaceutically acceptable adjuvants, carriers, excipients, and/or diluents.

7. The composition of claim 1, wherein the amount of said complement inhibitor or CD 14 pathway inhibitor is sufficient for dosages of 1 to 200 milligrams per kilogram of body weight per day.

10. The composition of claim 1 or 3, wherein the composition is for the prevention of sepsis.

11. The composition of claim 1 or 3, wherein the composition is for the treatment of sepsis.

3. A composition for administration to a patient in need thereof for the prevention or treatment of sepsis, comprising a bispecific antibody comprising a first binding element that binds C5a and a second binding element that binds CD14,

wherein the sepsis is induced by gram negative bacteria, and

wherein the composition can be administered by oral, rectal, nasal, topical, intradermal, subcutaneous, intravenous, intramuscular, intratracheal, or intraperitoneal means.

8. The composition of claim 3, wherein the amount of the bispecific antibody is sufficient for dosages of 1 to 200 milligrams per kilogram of body weight per day.

5. A kit for administration to a patient in need thereof for the prevention or treatment of sepsis, comprising a complement inhibitor and a CD14 pathway inhibitor, in separate containers,

wherein the complement inhibitor is an anti-C5a antibody or a binding fragment thereof,

wherein the CD14 pathway inhibitor is an anti-CD 14 antibody or a binding fragment thereof,

wherein the sepsis is induced by gram negative bacteria, and

wherein the complement inhibitor and CD14 pathway inhibitor can be administered by oral, rectal, nasal, topical, intradermal, subcutaneous, intravenous, intramuscular, intratracheal, or intraperitoneal means.

6. The kit of claim 5, wherein the amount of said complement inhibitor or CD 14 pathway inhibitor is sufficient for dosages of 1 to 200 milligrams per kilogram of body weight per day.

9. The kit of claim 5, wherein the anti-CD14 antibody has altered effector functions of the Fc region.

12. The kit of claim 5, wherein the kit is for the prevention of sepsis.

13. The kit of claim 5, wherein the kit is for the treatment of sepsis.